Aramark (ARMK) Q4 2025 earnings review
Record New Business Fuels Strong Outlook Despite Q4 Profit Squeeze
Aramark reported a quarter of two stories: record-breaking commercial success offset by a significant short-term hit to profitability. Organic revenue grew an impressive 14% YoY, boosted by an extra week of operations. More importantly, the company secured a record $1.6 billion in new business for the year, including its largest-ever U.S. contract with Penn Medicine. However, this success triggered a $25 million incentive bonus payout and, combined with higher medical costs, caused adjusted EPS growth to decelerate sharply to just 6% YoY. Management expressed high confidence that these are manageable issues, issuing strong FY26 guidance for 20-25% Adjusted EPS growth, signaling that the powerful momentum in new client wins will drive future results.
🐂 Bull Case
The company achieved record annualized Net New business of 5.6% of prior year revenue, driven by $1.6 billion in gross wins and a historically high 96.3% retention rate. This provides strong visibility for growth in FY26.
The outlook for FY26 projects an acceleration in profitability, with AOI guided to grow 12-17% and Adjusted EPS guided up 20-25%. This suggests management views the Q4 profit headwinds as temporary.
The company reduced its leverage ratio to a 20-year low (3.25x), increased its dividend by 14%, and is actively repurchasing shares, signaling confidence in its cash flow generation and financial stability.
🐻 Bear Case
Adjusted EPS growth slowed dramatically to 6% from ~30% in Q3. This negative operating leverage (profit growing slower than sales) was driven by higher incentive and medical costs that may not be entirely one-time in nature.
The core FSS United States segment saw its adjusted operating income grow just 2% in the quarter, a significant underperformance compared to the International segment's 31% growth, indicating specific margin pressure in the largest market.
The timing of some large new account openings, including the massive Penn Medicine contract, was pushed into FY26. The company's ability to hit its strong guidance now hinges on successfully managing these large-scale, complex transitions.
⚖️ Verdict: 🟢
Bullish. The core long-term value driver for Aramark is winning and retaining profitable contracts, and FY25 was a record year on that front. The Q4 profit weakness is a direct result of this success (paying bonuses for wins) and other manageable costs. The strong FY26 guidance reflects the underlying health and momentum of the business, making the bull case more compelling.
Key Themes
Record Commercial Wins Set the Stage for FY26
Aramark's growth engine is firing on all cylinders. The company reported $1.6 billion in annualized gross new business wins, up 12% from the prior record year. Combined with a best-in-class client retention rate of 96.3%, this resulted in Net New business of 5.6% of prior year revenue, well ahead of the 4-5% target. The flagship win was the University of Pennsylvania Health System, the largest contract in FSS U.S. history, which begins in early 2026 and highlights the company's success in the attractive first-time outsourcing market.
Profit Growth Squeezed in Q4 by Costs
A contradiction to the positive sales narrative, Q4 profitability showed significant weakness. Despite 14% revenue growth, Adjusted Operating Income (AOI) grew only 6%, indicating negative operating leverage. Management attributed this to two main factors: a $25 million increase in incentive compensation tied directly to the record new business wins, and a $5 million headwind from higher medical prescription claims (specifically GLP-1s). While the company has taken action to curb future medical costs, the sharp deceleration in profit growth warrants close monitoring.
International Segment Continues to Outperform
The FSS International segment was the star performer in Q4, delivering another quarter of strong results. Organic revenue grew 14% and constant-currency adjusted operating income surged 31% YoY. This performance was broad-based, with particular strength noted in the U.K., Canada, Ireland, Spain, and Latin America. The segment's consistent double-digit growth and significant margin expansion provide a powerful and diversified earnings stream for the company.
Strengthened Balance Sheet and Capital Returns
Aramark ended the year with its leverage ratio at 3.25x, the lowest level in nearly 20 years. This financial strength and strong free cash flow generation (up 41% to $454 million in FY25) is enabling a multi-faceted approach to shareholder returns. The company raised its quarterly dividend by 14% and repurchased over 4 million shares during the fiscal year.
Shift in Contract Timing Creates Execution Risk
Management noted that the start dates for several new contracts were shifted from late Q4 FY25 into early FY26. While this was done to ensure a smooth transition for clients, it means that achieving the strong FY26 guidance is now more dependent on the successful and timely ramp-up of an unprecedented level of new business, increasing near-term execution risk.
Other KPIs
The Net Debt to Covenant Adjusted EBITDA ratio improved to 3.25x from 3.41x a year ago, reaching its lowest level in nearly two decades. This deleveraging provides significant financial flexibility for growth investments and shareholder returns. The company is guiding for this to fall below 3.0x in FY26.
Free cash flow grew 41% year-over-year, driven by stronger operating cash flow and favorable working capital management. This robust cash generation underpins the company's capital allocation priorities, including the recently increased dividend and share repurchase program.
Guidance
Accelerating. This guidance implies an acceleration from the underlying 5% organic growth delivered in FY25 (excluding the 53rd week). The growth is expected to be driven by the full-year contribution from the record new business wins secured in FY25.
Accelerating. This range represents a significant step-up from the 12% CC growth in FY25 and a sharp reversal from the 6% growth in Q4. It implies meaningful margin expansion as the company laps the one-time Q4 costs and benefits from the scale of its new contracts.
Accelerating. The midpoint of 22.5% represents an acceleration from the 19% CC growth in FY25. This reflects confidence in both operating profit growth and disciplined capital management.